LifeSci Continuum with Bill Schick

Have the engineering plan but need the market plan? Hire a Fractional CMO to de-risk launch and accelerate adoption. 

Book a strategy call.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

President/CEO Tim Looney (Northeast Biomedical) breaks down the engineering plan founders actually need (DHF, phased reviews, and right-sized documentation) to move faster without tripping FDA/CE. We cover startup blind spots, big-company constraints, and how to “do it right once” so you don’t pay for DHF remediation later.

Tim’s LinkedIn - https://www.linkedin.com/in/tlooney/ 

00:00 Why med device engineering fails
00:16 Who is Tim Looney
03:04 What founders miss in early engineering
06:11 Why the FDA rejects “it’s all in my head”
08:13 Hidden tests and documentation you must plan for
12:24 Move fast the right way
15:53 How phased engineering speeds up approvals
20:23 How to avoid costly founder mistakes
24:44 Why the system blocks unprepared founders
27:11 Case study on fast clearance done correctly
 
In medtech, “move fast and break things” breaks people. Tim Looney leads Northeast Biomedical, a product development and contract manufacturing firm that lives where speed meets compliance. In this episode, Tim explains the engineering plan most founders skip: phase-gated reviews, checklists that prevent “oops” moments at submission, and documentation that’s lean early but complete enough to avoid costly DHF remediation. We unpack startup blind spots (biocompatibility, shelf-life, packaging, verification), how larger companies get stuck in resource bottlenecks, and why the fastest path to clearance is often meticulous—just not bloated. Tim also shares a class-III European dossier story that moved in weeks because the package was complete, plus practical guidance for early founders on prototypes, notebooks, and IP strategy. If you’re building the next device, this conversation is your map to “right the first time.”

 https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

#MedTech #MedicalDevices #GoToMarket

Not seeing investor-grade pipeline from your science? Bill is the Fractional CMO for complex medtech & life-sci GTM. Book a 20-min diagnostic.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ 

• Connect with Dave Iannetta on LinkedIn: https://www.linkedin.com/in/dave-iannetta/
• Subscribe to Bill Schick’s Newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7154518390324281344

00:00 The IPO Playbook
02:30 Being Unprepared for IPO
04:30 Data & Market Validation
06:05 FDA Changes in 2025
09:27 Tips for Creating an IPO Deck
13:23 Messaging for IPO

About this episode: Early funding rounds reward vision, but the IPO process rewards verification. David joins me again to walk through the journey from institutional capital to public offering and shows how every assumption that once lived in a slide note must now survive legal discovery. He recalls deals that stalled because total-addressable-market figures lacked primary sources and others that crumbled when an FDA setback forced a last-minute pivot the team could not explain. His core message: a marketer’s real job at this level is to translate complex clinical value into a dollar-based opportunity that bankers can model and retail investors can grasp in two sentences.

Three IPO Musts: 
1. Treat market sizing the way a biostatistician treats a primary endpoint. Start with bottom-up data such as procedure volumes from CMS, epidemiology registries, or detailed purchase-order pulls from group-purchasing organizations. Build the model cell by cell so any analyst can trace volume, price, and adoption-rate assumptions back to a public document or a signed customer quote. Keep totals in three buckets—total addressable market, serviceable market, and realistically obtainable share—so you are never accused of using a single inflated figure. A grounded model not only survives diligence but also shapes banker sentiment; if you claim a four-billion-dollar market and the underwriters later pin it at one, you can lose half your valuation before the first road-show slide appears.

2. Create a living archive for every assumption that feeds your financials. Store PDFs of journal articles, invoices that justify cost inputs, raw spreadsheets, and even audio transcripts of expert interviews in a well-indexed data room. Each time a figure changes—perhaps because new coding data arrive or the FDA requests a larger trial—update the archive and note the version in your working deck. Bankers, lawyers, and syndicate analysts will audit each cell in your spreadsheet against its original source; if you have to scramble for proof after the S-1 is filed you will burn weeks, pay extra legal fees, and lose the momentum that makes an IPO window attractive in the first place.

3. Build your narrative as a living document that flexes with every regulatory update or clinical read-out. Investors do not punish a company for hitting a speed bump; they punish it for ignoring the bump or pretending it did not happen. Hold regular “story scrubs” where marketing, clinical, and finance teams rewrite the pitch deck in light of the latest data, resize the market if endpoints shift, and script a clear path forward. Practising this iterative storytelling prevents the deer-in-the-headlights moment when a diligence call surfaces new questions and shows investors that the team can navigate uncertainty as confidently as it develops science.

For more specialized help with growth, check out my firm, Mesh.
https://meshagency.com/ 

#IPOReady #LifeScienceMarketing #MarketSizing

Ready to launch faster? A fractional CMO can help. Talk to MESH. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Founder Peter Attia built Family Vitals, an iOS app that helps families securely organize, collaborate on, and understand their medical records—without reinventing a risky data stack. We cover validation before code, scoping to ship, leveraging Apple Health, surviving App Store review, and why security is the feature. Great listen for solo founders and health-tech teams.

Peter Attia, founder of Family Vitals: https://www.linkedin.com/in/peter-attia-90945052/ 
Family Vitals: https://www.familyvitals.com/ 

00:00 Why this app began, family pain to product idea
02:14 What Family Vitals does (iOS, collaboration, AI)
04:18 Solo founder build, whiteboard to design to code with AI
07:25 Why iOS first, cost, HIPAA, and not hosting data
10:02 MVP focus and early validation (surveys, willingness to pay)
15:10 Tech surprises and Apple review realities
19:34 Platform leverage, Apple Health vs rebuilding integrations
20:11 What he would do differently, talk to devs, prelaunch list, outsource brand
28:35 Setbacks and plan B during review
30:20 Security and trust, document everything, treat data as core

Peter, a software engineer with a data/analytics background, built Family Vitals, an iOS app that lets families securely store, organize, and collaborate on medical records, notes, images, and lab reports—while pulling data via Apple Health from thousands of clinics and hospitals. He explains why he chose iOS first (security posture, cost, infrastructure leverage), how AI sped up 30–40% of the busywork (but not the architecture), and why scoping ruthlessly was the only way to ship.

We dig into market validation (conversations + survey with the “sandwich generation”), navigating a multi-month App Store review for medical data, and the choice to use the platform’s rails rather than roll his own HIPAA-heavy backend. Peter shares what he’d change—start lead collection months earlier and partner on branding/positioning sooner—and leaves builders with a clear mantra: validate early, document security, and stack your work so launch momentum isn’t an accident.

3 Founder Moves Peter Used to Ship Faster

Tip 1 — Validate before you code (and build a waitlist):
Run 15–25 quick interviews with your target “family manager” persona + a lightweight 4–6 question survey to size the pain and test willingness to pay. Stand up a 1-page teaser + email capture and drive $10–$20/day traffic for two weeks. Green-light if you see ≥50–60% positive intent, ≥20% signup rate, and clear top-5 “must-have” features. Parking-lot the rest for later.

Tip 2 — Ruthless scope via platform leverage:
Pick ONE platform that removes risk. For health data, iOS first can unlock HealthKit/Apple Health connectivity, native security rails, and faster build loops. Design your MVP around the smallest end-to-end journey (e.g., import record → add note → share with family) and trim anything that slows App Review. 

Tip 3 — Security-first from Day 0 (document everything):
Assume regulators, platforms, and partners will ask “how do you protect PHI?” Create a living security pack: data-flow diagram, storage decisions (avoid holding what you don’t need), access controls, audit trails, breach response, and privacy policy. Align features to what platforms will approve now (text-only chat before advanced agents, etc.). This prep shortens review cycles and builds user trust you can market—screenshots of your security posture, not just UI.

Need go-to-market firepower? Book MESH. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

#HealthTech #FounderJourney #DigitalHealth

Find out how a Fractional CMO can get the right questions answered from the right audience. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
- Connect with Bill https://www.linkedin.com/in/founderandcdo/

Jim MacLeod Designer-turned-marketer, brand systems builder, and author of The Visual Marketer—a field guide that translates design fundamentals for marketers and founders.
- Connect with Jim MacLeod: https://www.linkedin.com/in/jimmacleod/
- Jim’s Book: https://book.jimmacleod.com/

Struggling to make great tech look inevitable? Bring in MESH as your fractional CMO to turn brand, web, and product storytelling into qualified pipeline.

Designer-turned-full-stack marketer Jim MacLeod breaks down why “good enough” visuals stall growth, how he led a 90-day rebrand without losing brand equity, and the small design choices that decide whether your product gets tried…or ignored.

00:00 Intro — brand fragmentation & growth roadblocks
01:12 Meet Jim Macleod — design, marketing & brand systems
04:17 Case study — 90-day rebrand under Apple-style deadlines
08:27 Why keep the purple? Modernizing without losing equity
12:25 Outdated design vs. innovative tech — fixing the disconnect
16:08 Sales decks & storytelling — shaping the brand narrative
18:10 Customer support as brand — protecting what matters in acquisitions
20:32 Bridging design & marketing — lessons from The Visual Marketer
25:00 Three essentials founders can’t DIY: logo, colors, consistency
31:00 Why first impressions matter — design as trust and credibility
35:09 Trade shows & booth design — why presentation drives traffic
39:10 When to invest in brand — moving beyond referrals
42:12 Copy vs. design — which comes first, and why both matter
45:57 Final thoughts, book link & wrap-up

Founders swear “the tech sells itself.” Buyers don’t. In this episode, Jim MacLeod shows how small visual decisions snowball into trust, attention, and adoption. He walks us through a compressed 90-day rebrand, explaining why his team kept the legacy color (because the market already mapped it to credibility) while modernizing everything around it. 

Brand Swagger: Jim’s 3 No-BS Design Wins

- 1) Codify your visual system—once.
 Stop “designing from scratch” every asset. Build a one-page brand kit that nails your type hierarchy, color roles, spacing grid, icon style, motion rules, and image treatment (e.g., duotone, depth, lighting). Turn those into tokens in your CMS/Slide master so the choices are baked in. Result: faster production, fewer off-brand detours, and a look that’s unmistakably you across web, decks, UI, and booths.

- 2) Color with intent, not taste.
 Pick an ownable anchor color (distinct in your category), pair it with two neutrals for clinical credibility, and reserve one accent for calls-to-action and data highlights. Pressure test it in the wild: accessibility contrast, print vs. screen, scrubs/OR lighting, tradeshow LEDs, and dark mode. If it fails anywhere your buyers live, it’s not your color system—it’s a liability.

- 3) Design the first impression you can’t afford to miss.
 Prioritize the touchpoints that actually sell: homepage hero, product shell/packaging, sales deck front half, and 10×10 tradeshow booth. Make them story-led (problem → outcome → proof), ruthless on clarity (one idea per screen), and visually scannable at six feet. Then measure like a grown-up: booth dwell time, deck completion rate, hero click-through, and demo requests tied to those assets. If it doesn’t move pipeline, it’s just decoration.

For more specialized help with growth, check out my firm, Mesh.
https://meshagency.com/ 

#DesignThatSells #MedTechMarketing #FractionalCMO

Find out how a Fractional CMO can get the right questions answered from the right audience. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Connect with Bill https://www.linkedin.com/in/founderandcdo/

Connect with Dave Kern https://www.linkedin.com/in/david-kern-dkny/

Product stalls aren’t engineering problems—they’re listening problems. Dave Kern joins us to unpack practical Voice of Customer (VOC), why brand awareness matters before the sales call, and simple, low-cost ways to validate direction without bias.

00:00 Brand awareness & Why VOC isn’t optional
01:36 Meet David Kern — data over opinions
05:15 VOC 101: quant vs. qual, why it matters
07:25 Case study: “our users aren’t on social”… until the data says they are
12:49 From low awareness to lift: education-first digital done right
15:25 What sales wishes prospects knew before the meeting
18:10 Simplify the science; visuals that help, not distract
22:53 Getting buy-in: start small → scale VOC
26:09 Selling into systems: trust, advocates & avoiding “me-too”
31:08 Quick wins: tap networks + one-question polls
40:39 Segmentation, hidden influencers & avoiding bias
47:31 Wrap-up

Too many teams “build it and they will come.” 

They won’t. 

Dave Kern breaks down how Voice of Customer turns foggy assumptions into crisp direction—so marketing educates, sales accelerates, and product lands. We talk brand warm-up (why strangers won’t buy), short educational content that stops the scroll, and how to run quick, bias-resistant validation without a six-figure research budget. Dave shares practical patterns: use social polls to test beliefs fast, ask the Five Whys to get past surface answers, and interview the people who didn’t buy to find the real friction. We also cover avoiding KOL-only echo chambers, sizing the true reachable audience, and framing VOC for execs who want outcomes, not research theater.

Stop Guessing, Start Hearing: Dave Kern’s 3 VoC Power Plays
Tip 1 — Pre-commit to the decision your question will drive:
 Before you draft a survey or book interviews, list the 3–5 product/marketing decisions you’ll make based on the answers (e.g., “If ≥60% say X, we build Feature A first”). Use a tight, 10-question cap, apply the Five Whys to 2–3 core items, and split audiences (KOLs vs. everyday users). Aim for a fast N=20 “sanity pass” via short calls + one-click social polls; anonymize responses so titles don’t sway outcomes.
Tip 2 — Warm the market while you listen (90-day runway):
 Run education-first content (problem → science → implication) in paid/organic social to the exact audience you’re interviewing. Ask sales, “What do you wish they knew before you walk in?” and turn that into 60–120s explainers. Tag everything with UTMs, equip reps with the same assets, and track leading indicators (video completions, return visitors, branded search) so brand lift and VoC learnings compound.
Tip 3 — Design out bias in the room and the sample:
 Don’t let KOLs speak for the market. Include “no” and “lost” accounts, set a quota for late-majority users, and add 3–5 disconfirming interviews. In workshops use silent ideation → dot-vote to equalize voices, time-box discussion, and name a single decision-maker with a decision deadline. Document assumptions in a one-pager and “red team” them before you spend.

Burning budget on noise? Audit with an FCMO → keep what works.
https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

#VoiceOfCustomer #MedtechMarketing #GoToMarket

Partner sprawl stalling progress? A Fractional CMO prioritizes what moves revenue now. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ 

Connect with Greg Lange
https://www.linkedin.com/in/greg-lange-70bab04/

Early-stage medtech moves faster with the right partners. Greg Lange (Symbex) shares how to de-risk early, pick partners you can trust, and keep product + commercialization in lockstep. We cover founder archetypes, when to bring in reg/reimbursement, and the operating cadence that avoids “beautiful dead ends.”

00:00 – Who’s Greg & what Symbex does — design + commercialization under one roof
03:00 – Why partnerships matter — big-co vs startup dynamics; treat partners like partners
08:30 – The Maine case — MVP first, then V2; commercialization before “perfect”
13:30 – Founder archetypes — clinician, engineer, entrepreneur; typical misses and how to cover them
20:00 – When to bring in experts — reg, reimbursement, competitive scan; sprint without blinders
27:30 – Partner-first strategy — recruiting talent & capital by selling the vision early
33:00 – How to choose partners — trust signals, communication, no-surprises rule, say-no credibility
40:00 – Requirements & communication — MV-requirements, cadence, shared dashboards
46:00 – Budget & burn — share constraints, co-scope the work, optimize for speed-to-learning
50:00 – Three practical tips — align on mission, quarter-by-quarter deliverables, treat partners like key hires

Founder Field Manual: Three Moves That Save You Months

1) Start With the Story, Not the Spec.
 Before you sprint into building, write the one-page vision that explains why this exists, who it’s for, and how it wins. Share it with three people who would buy, use, or fund it and ask, “What’s missing?” This gives partners a north star, helps you say no to shiny objects, and turns early collaborators into advocates—because they can see where you’re going and how they fit.

2) De-Risk in Days, Not Quarters.
 Run a “week-one gauntlet”: a quick regulatory path read, a reimbursement/payor sanity check, and a 10-call voice-of-customer sprint. You’re not seeking perfection—just red-flag hunting. If a pathway, payment, or workflow blocker pops, pivot your scope now (MVP to masterpiece). This keeps burn pointed at validation instead of vanity, and it arms you with credible evidence when you talk to investors.

3) Choose Partners Like Co-Founders.
 Don’t outsource and hope—co-build and verify. Use a minimum viable requirements doc (one page is fine) and a no-surprises cadence (weekly 30-min sync + transparent task board). Favor partners who push back with alternatives (“no, and here’s the path”) over order-takers. Share your constraints—including budget—so they can design scope that actually ships. Trust, speed, and clear accountability beat rock-star resumes every time.
Founder energy is real—but so are bottlenecks. Greg Lange, President & CEO at Symbex, breaks down how early-stage teams can use partnerships to de-risk, shorten timelines, and build products the market will actually buy. We cover founder archetypes (clinician, engineer, entrepreneur), when to bring in regulatory/reimbursement, what a “good partner” looks like, and why sharing your budget is a trust signal—not a weakness.

#MedTech #Partnerships #Startup

Stuck in gridlock? Learn how a Fractional CMO can transform misalignment into momentum. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Connect with Bill: https://www.linkedin.com/in/founderandcdo/

Connect with Kata: https://www.linkedin.com/in/katalinszegner/ 

Biotech product leader Katalin “Kata” Szegner shares how to replace meeting chaos with structure: silent ideation, equal airtime, clear decision ownership, and customer-centric differentiation. We cover ending gridlock, aligning R&D with commercial, and making workshops produce real decisions—not more meetings.

00:00:00 Intro
00:01:57 Meet Kata, Teacher to Project Manager in Biotech
00:02:56 Teaching skills that supercharge product teams
00:08:12 Where misalignment starts (R&D vs. commercial)
00:10:58 Founders vs Customers, Ambition vs Traction, Growth vs. Compliance
00:16:32 Equal voices: silent ideation, dot voting, decision roles
00:26:12 Case: 18-month stall solved in hours by surfacing hidden insight
00:36:32 Workshop setup: boundaries, objectives, timeboxing, decision maker present
00:40:00 How to Set Boundaries
00:42:22 Visual frameworks that unlock clarity (Hot Air Balloon, etc.)
00:46:42 Foundation sprint & customer-centric differentiation
00:50:00 Marketing early: jobs-to-be-done and VOC as strategy, not afterthought
00:52:12 Wrap: courage, cadence, and the value of a neutral facilitator

Today’s guest, Katalin “Kata” Szegner, moved from the biology classroom to leading complex biotech products—and brought the secret with her: it’s not “clarity first,” it’s connection first. Kata shows how misalignment takes hold (founders’ vision vs. feasibility, R&D rigor vs. commercial urgency) and how to replace it with lightweight structure.

We unpack silent ideation to hear the quiet 80%, dot voting to separate ideas from egos, and clear decision ownership so meetings end in movement. Kata shares a vivid example where a team spun for 18 months—until a structured session surfaced the missing technical truth and unlocked a fix in hours.

You’ll get a simple toolkit for workshops that work: set boundaries (phones down, time blocked), publish the objective, assign the decider, and use visual frameworks (e.g., Hot Air Balloon) to make complex tradeoffs tangible. We close on customer-centric differentiation and why marketing must be present from phase zero—not as an afterthought once the science is “done.”

From Gridlock to Go: 3 Alignment Fixes Pros Miss

Equalize the room with silent ideation.
 Kick off key discussions heads-down: 60–120 seconds of quiet writing on cards or stickies before anyone speaks. Then de-dupe, group, and dot-vote. This prevents “first-voice contamination,” surfaces the 80% who rarely talk, and gives you a ranked input set to work from.

Put a decider in the room—explicitly.
 Name the decision-maker up front and confirm their attendance for the full session. Timebox each segment, finish with a single documented decision, owner, and next step. Set simple guardrails (no laptops/phones, full-day focus) so the group can actually decide, not just discuss.

Do the prework to remove surprises.
 Before the workshop, interview stakeholders, map who must be present (and influential absences), list known assumptions, and define success criteria. Bring 1–2 visual frameworks (e.g., Hot-Air Balloon) and a strawman/prototype to test the highest-risk assumption first. This turns the session into validation, not discovery.

Continue your founder’s journey with another episode: https://www.youtube.com/playlist?list=PLibD2fYYaAIISuFLmIXfzrh9_QgB9E2u8

#Biotech #ProductManagement #MedTech

Work with Bill: https://meshagency.com/lets-connect/

- Aaron Joseph https://www.linkedin.com/in/ajosephprofile/
- Russ Singleton https://www.linkedin.com/in/russellsingleton/ 

Here’s the link to their blog series: https://www.mpo-mag.com/author/russell-m-singletonrodmaneditors-mpo-com/

00:00 Introduction and guest bios (Aaron Joseph & Russ Singleton)
01:40 Backgrounds in medtech, compliance, and product development
03:40 What is Phase Zero in medical device development?
05:30 Why skipping Phase Zero leads to compliance & product failures
07:00 The physician-inventor dilemma: “I am my own customer”
10:30 Early adopters vs. mainstream market realities
13:00 Phase Zero on steroids: knowledge-building, risk reduction, and planning
19:00 Success through feasibility checks, fail-fast pivots, and market validation
25:00 Jobs-to-Be-Done, customer discovery, and avoiding founder bias
41:00 Practical advice for clinicians and teams starting innovation journeys
50:30 Final thoughts: passion, customer focus, and long-term impact

Medtech veterans and co-authors/thought leaders Aaron Joseph (Sunstone Pilot) and Russ Singleton unpack “phase zero on steroids”—the disciplined, pre-development work that de-risks science, validates real jobs-to-be-done, and sets your regulatory and reimbursement strategy before you write a line of code. Expect war stories, practical frameworks, and the permission to cancel projects early (that’s a win).

Most early-stage device teams rush into development and end up paying for it in rework, delays, or regulatory dead ends. In this episode, I chat with Aaron Joseph—principal consultant at Sunstone Pilot—and Russ Singleton—results-driven medtech executive and company builder. Aaron and Russ show you how to run Phase Zero on Steroids.

Three Tactics to Make Your Phase 0 Worthwhile
Russ and Aaron have three key takeaways for your med-tech journey pre-development, all with the promise of reducing headaches when executed properly.

Front-Load Truth, Not Features.
Begin Phase Zero by naming the job-to-be-done in one plain sentence and testing it with a representative set of users—not just top-5% surgeons. Pair a market-ear with a technology-ear in every interview to capture both desirability and feasibility. Write down kill criteria (technical, clinical, regulatory, economic) you’ll honor. If you hit them, pivot or stop. Canceling early is a success that preserves runway.

Make Science a Workstream with Exit Gates.
 Treat unknowns like experiments: define the question, the method, the success threshold, and the next decision. Time-box these studies and document what you learn so results flow directly into design inputs. In parallel, map regulatory strategy (e.g., 510(k) vs PMA), evidence requirements (clinical/usability/electrical safety/sterilization), and reimbursement hypotheses. Often the fastest market path is a tight v1.0 with limited indications that establishes a regulatory baseline.
Design for Adoption Across Four Buyers.

 You’re not just convincing a clinician—you’re convincing a system. Quantify switching costs and plan proof that speaks to (1) the user, (2) the hospital/economic buyer, (3) the payer/reimbursement gate, and (4) internal champions. Build your go-to-market around early centers that match your first winning application, then expand indications. Keep Phase Zero lean but funded: small, passionate core team; targeted outside experts; a 5-page plan that a VC—or your own GM—can say yes to.

Want help turning messy early insights into a crisp strategy, message, and launch plan? Bring in a Fractional CMO.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

 #MedTech #MedicalDevices #healthcareinnovation

Contact Bill: https://meshagency.com/lets-connect/

Follow Jack O’Callaghan - https://www.linkedin.com/in/jack-o-callaghan-5672636/ 

Founders don’t fail for lack of ideas—they fail for ignoring payers, regulators, and real user needs. Today I sit down with Jack O’Callaghan (Director, Business Development, Northeast Biomedical) about this very challenge. Jack explains why “build it and they will come” collapses in medtech. We get practical about payer and regulatory realities, user-needs documents, TAM fantasies, voice-of-customer, KOL strategies, and why v1.0 is never the finish line.

00:00 Why the system won’t say “yes” by default
01:27 Jack’s path: pharma → devices → engineering services
03:08 What Northeast Biomedical actually builds
04:20 Examples: reagent processor (goat blood for lateral flow), vision-guided robots, drug-delivery catheters
05:10 Where founders underestimate the journey
08:33 Reimbursement reality: enteral feeding example
12:11 You don’t sell to a person; you sell into a system
17:00 Medicine as art: implications for product design
22:56 TAM delusions and setting reachable targets
26:09 DoD “I just need to find the right person” myth
31:00 Time, bandwidth, and the cost of learning everything yourself
36:02 Prototypes, investors, and exit clarity
41:03 “I just need a distributor” (no, you don’t)
43:07 Start with user needs (engineering + commercial)
45:14 Garage prototypes and the laws of physics
47:22 Admit what you don’t know—then staff it

Three Moves That Shorten the Road to Adoption
Be realistic and think about the entire product journey. Most founders pitch a giant TAM and assume clinicians will pull the product through. Replace that with a real adoption plan. Define the serviceable market you can actually reach in the first 12–24 months, by site type and procedure volume. Map the buying center for each site: the clinical champion, the economic buyer, supply chain, biomed, and IT. Tie your value to what each of them cares about. If your claim is time saved, translate it to minutes per case and the OR cost per minute. If you reduce complications, translate it to fewer readmissions and avoid penalties. Engage payers early to confirm coding, coverage, and payment so the business case survives first contact with reality.

Admit what you don’t know and hire it early. Speed comes from admitting what you do not know and buying the right help early. Before you touch CAD again, lock a one-page user needs document and a preliminary regulatory and reimbursement path. Do a quick freedom-to-operate check. In parallel, bring in fractional experts for regulatory, quality, reimbursement, clinical affairs, and product marketing. Their fees are small compared with the cost of delay or a redesign that shows up after your first animal lab. A class II pathway can reach into the tens of millions and beyond; every month you shave by parallelizing workstreams and avoiding rework is real money and earlier evidence.

Plan to learn fast rather than launch perfect. Treat version 1 as the instrument you use to collect voice-of-customer and usability data that informs version 2 and 3. Schedule bench, cadaver, or animal sessions and capture structured feedback. Build a small KOL council and put them on a cadence. Document changes, train on the procedure, and collect outcomes that quantify your promise in terms the system buys: OR minutes avoided, length of stay reduced, fewer transfers, fewer reoperations. Line those metrics up with your coding and payment story so clinical and financial value show up in the same frame.

If your deck still shows a massive TAM but you lack a sequenced GTM, bring in a fractional CMO to convert user needs and payer logic into a market-access plan that actually moves revenue: https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

#MedTech #MedicalDevices #MarketAccess

Connect with Bill on LinkedIn: https://www.linkedin.com/in/founderandcdo/

Discover how an on-demand Fractional CMO can sharpen your story and accelerate growth—visit https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Follow Elizabeth: https://www.linkedin.com/in/elizabethnoellumpkin/ 

00:00 Intro
02:30 Miscommunication in Medicine
06:40 Founders Miscommunication
11:35 Assumptions in Language
14:25 Identifying Your Audience
16:40 Communicating Painpoints & Needs
20:32 Credentialing
23:05 Founders Communicating to Customer
31:00 Methods for Sharing Ideas with your Founder
35:30 Trade Journal Ads
37:00 Problem vs Product
40:52 Avoiding Revolutionary Language
41:32 Advice for Founders

Medicine brims with life-saving innovation, yet audiences still tune out because the language feels alien. Today I sit down with Noel as she outlines a three-step playbook for breaking that cycle. First she shows how to pinpoint exactly who you are talking to and strip away insider shorthand that sabotages clarity. Next she demonstrates the power of storytelling—why a short patient vignette sticks long after a bullet list of specs. Finally she maps features to stakeholders’ true pain points, from clinicians starved for time to hospital CFOs bleeding cash on readmissions. 

The result is messaging that earns trust, overcomes change resistance, and moves products off the brochure page and into everyday practice.

With that in mind, here are some recommendations to better connect with your audience. 

Name the Listener, Tell the Story, Pinpoint the Pain

Start every project by writing a single sentence that defines exactly who you are talking to. A sentence like “We help over-worked oncology nurses reduce charting time” forces you to picture a real person, not a demographic blur. Once that sentence is on paper, read every headline, slide, and web page aloud using the words your audience would use in a hallway conversation. Terms that sail through an R-and-D meeting often stall when the same words land in a clinic lobby. If a phrase raises eyebrows or needs a footnote, swap it for something plainer before it leaves your desk.

Next, turn your glossary into a library of short stories. Replace abstract benefits with moments your audience can feel. “Reduces post-op hypothermia” is a statistic; “Your patient wakes up warm instead of shivering” is a scene everyone remembers. Collect these scenes in a living archive so your sales deck, social posts, and regulatory summaries draw from the same human moments. Familiar stories travel farther than flawless jargon, and they build the trust that complex data alone rarely earns.
Finally, translate each feature into a tangible pain point. Show how shaving five minutes off an intubation saves two operating-room turnovers a day, or how a single avoided readmission keeps thirty thousand dollars in the hospital’s budget. When you frame benefits in time, money, or quality metrics that already keep stakeholders up at night, your pitch stops feeling like a nice-to-have and starts reading like an urgent line item.

#LifeSciences #HealthcareInnovation #ProductMarketing